Table 2:
Population characteristics and outcomes of the included studies.
| Study (Year published) | N | Males N (%) | Age yrs Mean (S.D) | BMI Pre-ESG (S.D) | Follow up (Months) | % TWL | % EWL | Serious Adverse Events N (%) |
|---|---|---|---|---|---|---|---|---|
| Saumoy (2018) | 128 | 42 (32.8%) | 43.6 (11.3) | 38.92 (6.95) | 6 | 13.43 (7.4) | NA | 2 (1.5%) (1 perigastric leak, 1 perforation) |
| 12 | 15.8 (9.5) | NA | ||||||
| Alqahtani (2019) | 1000 | 103 (10.3%) | 34.4 (9.5) | 33.3 (4.5) | 6 | 13.7 (6.8) | 64.3 (56.2) | 24 (2.4%) (8 severe abdominal pain, 7 post-procedure bleeding, 4 peri-gastric collections with pleural effusion, 5 post-procedure fever with no sequelae) |
| 12 | 15.0 (7.7) | 67.5 (52.3) | ||||||
| 18 | 14.8 (8.5) | 64.7 (55.4) | ||||||
| Abu Dayyeh (2017) | 25 | 4 (16%) | 47.6 (10) | 35.5 (2.6) | 6 | NA | 54 (40) | 3 (12%) (1 peri-gastric fluid collection, 1 pulmonary embolism, 1 pneumoperitoneum/pneumothorax) |
| 12 | NA | 54 (40) | ||||||
| 20 | NA | 45 (41) | ||||||
| Lopez-Nava (2017) | 154 | 46 (30%) | 44.9 (9.5) | 38.3 (5.5) | 6 | 15.8 (7.1) | 47.8 (29.4) | 0 (No SAE) |
| 12 | 18.2 (10.1) | 52.6 (31.3) | ||||||
| 24 | 19.5 (10.5) | 60.4 (31.1) | ||||||
| Morales (2018) | 148 | 27 (18.2%) | 41.53 (10) | 35.11 (5.5) | 6 | 15.45 (5.9) | 64.93 (51) | 1 (0.67%) Mild GI bleeding |
| 12 | 17.53 (7.57) | 75.4 (85.0) | ||||||
| 18 | 18.66 (7.3) | 79.25 (43) | ||||||
| Barrichello (2019) | 193 | 45 (23.3%) | 42.3 (9.6) | 34.11 (2.97) | 6 | 14.25 (5.26) | 56.15 (22.93) | 4 (2.07) (2 Gl bleeding, 2 perigastric fluid collections) |
| 12 | 15.06 (5.22) | 59.41 (25.69) | ||||||
| Sartoretto (2018) | 51 (Austr alia) | 15 (29.4%) | 43 (11. 9) | 36.7 (4.9) | 6 | 14.0 (5.6) | 49.2 (23.2) | 3 (2.6%) (2 Gl bleeding, 1 perigastric fluid collection) |
| 42 (US Ctr 1) | 17 (40.5%) | 49.2 (11.4) | 41.2 (8.0) | 6 | 16.3 (7.9) | 46.9 (20.3) | ||
| 19 (US Ctr 2) | 3 (15.8%) | 41.2 (8.0) | 33.6 (4.0) | 6 | 17.7 (1.7) | 72.1 (9.7) | ||
| Kumar (2017) | 22 | 2 (9.1%) | 39.2 (1.6) | 34.3 (1.0) | 6 | 17.3 (1.7) | NA | 0 (No SAE) |
| 12 | 17.3 (2.6) | NA | ||||||
| 77 | 18 (23.4%) | 41.3 ± 1.1 | 36.1 (0.6) | 6 | 16.0 (0.8) | NA | 0 (No SAE) |
|
| 12 | 17.4 (1.2) | NA |
*
NA data was not available
+
Percent total weight loss (%TWL); Percent Excess Weight Loss (%EWL); Standard Deviation (S.D.); Seriouse Adverse Event (SAE)